drugset / Trial / NCT06103513

Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children

NCT06103513

Phase 3 Unknown 50 enrolled Northwell Health
RandomizedParallel-groupSingle-blindTreatment

Summary

A prospective, randomized, open-label single-blinded study of 50 subjects with growth hormone deficiency, ages 5 to 15 years in which 25 subjects will initiate rhGH therapy at 0.3mg/kg/week and the remaining 25 subjects will initiate their rhGH treatment at 0.2 mg/kg/week for the first 12 months of treatment. Safety parameters, height velocity, and adult height prediction by bone age determination will be assessed at 4-month intervals for 1 year following the initiation of rhGH therapy.

Timeline

Start
2023-12-10
Primary completion
2025-06-10
Completion
2025-12-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatropin Protein / enzyme biologic 0.2 mg/kg Subcutaneous
Comparator Somatropin Protein / enzyme biologic 0.3 mg/kg Subcutaneous

Indications

No indication recorded.